JTC Employer Solutions Trustee’s Recursion Pharmaceuticals RXRX Stock Holding History

JTC Employer Solutions Trustee’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$44K	Hold	14,317	–	–	﹤0.01%	245
2025 Q4	$58K	Hold	14,317	–	–	﹤0.01%	241
2025 Q3	$70K	Buy	14,317 +11,925	+499%	+$62.6K	0.01%	228
2025 Q2	$12K	Hold	2,392	–	–	﹤0.01%	273
2025 Q1	$13K	Hold	2,392	–	–	﹤0.01%	283
2024 Q4	$16K	Hold	2,392	–	–	﹤0.01%	278
2024 Q3	$16K	Hold	2,392	–	–	﹤0.01%	287
2024 Q2	$18K	Buy	+2,392	New	+$20.9K	﹤0.01%	286

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JTC Employer Solutions Trustee's RXRX Position: Q1 2026 in Review

JTC Employer Solutions Trustee held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 14,317 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #245.

JTC Employer Solutions Trustee first reported a position in RXRX in Q2 2024 and has held it in 8 quarters since. The position peaked at $70K in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

JTC Employer Solutions Trustee held 14,317 shares of Recursion Pharmaceuticals worth $44K as of Q1 2026.
JTC Employer Solutions Trustee left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
Recursion Pharmaceuticals made up ﹤0.01% of JTC Employer Solutions Trustee's portfolio in Q1 2026, its #245 holding.
JTC Employer Solutions Trustee first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
JTC Employer Solutions Trustee's Recursion Pharmaceuticals position peaked at $70K in Q3 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on JTC Employer Solutions Trustee's 13F filing for Q1 2026, filed 19 May 2026.